Payment overview · 2025
General Payments
$701.09
31 reported records · 14 companies
Healthcare provider profile · identity verified
John R Feeney, D.O.
Allopathic & Osteopathic Physicians|Family Medicine|Adult Medicine · MURRIETA, CA · NPI 1528049475
Verified facts
What the public records show
CMS Open Payments records show John R Feeney, D.O. received $701.09 in general payments during 2025 across 31 reported records.
AstraZeneca Pharmaceuticals LP accounted for 26.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $183.49 | 26.2% | 8 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $88.13 | 12.6% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $84.75 | 12.1% | 3 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $62.25 | 8.9% | 3 | 2025 |
| Verity Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $48.86 | 7.0% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $35.78 | 5.1% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $34.24 | 4.9% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $32.63 | 4.7% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $31.49 | 4.5% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $25.81 | 3.7% | 1 | 2025 |
| Optinose US, Inc. | Unresolved — no canonical attribution shown | $21.88 | 3.1% | 1 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $20.17 | 2.9% | 1 | 2025 |
| Hologic Sales and Service, LLC | Unresolved — no canonical attribution shown | $16.30 | 2.3% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $15.31 | 2.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $701.09 | 31 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $115.36 | 5 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $100.93 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $88.13 | 4 | 2025 |
Source payment records
|
|||||
| Belbuca Normalized: belbuca |
Drug | Collegium Pharmaceutical, Inc. | $62.25 | 3 | 2025 |
Source payment records
|
|||||
| Tlando Normalized: tlando |
Drug | Verity Pharmaceuticals Inc. | $48.86 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $34.24 | 2 | 2025 |
Source payment records
|
|||||
| WaveWriter Alpha Prime 16 Normalized: wavewriter alpha prime 16 |
Device | Boston Scientific Corporation | $32.63 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $32.31 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $32.31 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $31.49 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $27.34 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $25.81 | 1 | 2025 |
Source payment records
|
|||||
| PENMENVY Normalized: penmenvy |
Biological | GlaxoSmithKline, LLC. | $25.10 | 1 | 2025 |
Source payment records
|
|||||
| Xhance Normalized: xhance |
Drug | Optinose US, Inc. | $21.88 | 1 | 2025 |
Source payment records
|
|||||
| JATENZO Normalized: jatenzo |
Drug | TOLMAR, INC. | $20.17 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $18.40 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $18.40 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $17.38 | 1 | 2025 |
Source payment records
|
|||||
| APTIMA Normalized: aptima |
Device | Hologic Sales and Service, LLC | $16.30 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $15.31 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 353 | 111 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 306 | 44 |
| Atorvastatin Calcium | Atorvastatin Calcium | 294 | 91 |
| Levothyroxine Sodium | Levothyroxine Sodium | 247 | 75 |
| Lisinopril | Lisinopril | 206 | 65 |
| Alprazolam | Alprazolam | 198 | 43 |
| Tamsulosin Hcl | Tamsulosin Hcl | 148 | 47 |
| Metformin Hcl | Metformin Hcl | 147 | 48 |
| Carvedilol | Carvedilol | 141 | 38 |
| Gabapentin | Gabapentin | 138 | 41 |
| Omeprazole | Omeprazole | 134 | 44 |
| Hydrochlorothiazide | Hydrochlorothiazide | 131 | 35 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 128 | 38 |
| Losartan Potassium | Losartan Potassium | 120 | 36 |
| Furosemide | Furosemide | 114 | 39 |
| Metoprolol Succinate | Metoprolol Succinate | 113 | 34 |
| Azithromycin | Azithromycin | 110 | 65 |
| Pantoprazole Sodium | Pantoprazole Sodium | 110 | 36 |
| Sertraline Hcl | Sertraline Hcl | 95 | 34 |
| Alendronate Sodium | Alendronate Sodium | 92 | 30 |
| Atenolol | Atenolol | 91 | 25 |
| Oxycodone Hcl | Oxycodone Hcl | 91 | suppressed |
| Eliquis | Apixaban | 89 | 22 |
| Simvastatin | Simvastatin | 86 | 24 |
| Valsartan | Valsartan | 79 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 75 | 22 |
| Montelukast Sodium | Montelukast Sodium | 75 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 72 | 20 |
| Temazepam | Temazepam | 69 | 18 |
| Trazodone Hcl | Trazodone Hcl | 69 | 26 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 67 | 26 |
| Donepezil Hcl | Donepezil Hcl | 66 | 20 |
| Potassium Chloride | Potassium Chloride | 64 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 63 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 62 | 23 |
| Escitalopram Oxalate | Escitalopram Oxalate | 61 | 15 |
| Tramadol Hcl | Tramadol Hcl | 58 | 22 |
| Allopurinol | Allopurinol | 55 | 15 |
| Metoprolol Tartrate | Metoprolol Tartrate | 53 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 53 | 17 |
| Clonazepam | Clonazepam | 51 | suppressed |
| Folic Acid | Folic Acid | 50 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 49 | 22 |
| Fenofibrate | Fenofibrate | 48 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 48 | 13 |
| Prednisone | Prednisone | 47 | 19 |
| Ibuprofen | Ibuprofen | 46 | 20 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 46 | 18 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 44 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 42 | 14 |
| Diazepam | Diazepam | 41 | 11 |
| Estradiol | Estradiol | 40 | 16 |
| Fluconazole | Fluconazole | 40 | 19 |
| Metformin Hcl Er | Metformin Hcl | 40 | 14 |
| Clonidine Hcl | Clonidine Hcl | 39 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 39 | suppressed |
| Lorazepam | Lorazepam | 38 | 15 |
| Memantine Hcl | Memantine Hcl | 38 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 37 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 35 | 30 |
| Morphine Sulfate Er | Morphine Sulfate | 34 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 33 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 33 | 13 |
| Promethazine Hcl | Promethazine Hcl | 33 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 32 | suppressed |
| Xarelto | Rivaroxaban | 32 | suppressed |
| Lovastatin | Lovastatin | 30 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 30 | suppressed |
| Amoxicillin | Amoxicillin | 29 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 29 | 11 |
| Nystatin | Nystatin | 29 | 12 |
| Synthroid | Levothyroxine Sodium | 29 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 28 | suppressed |
| Cephalexin | Cephalexin | 27 | 16 |
| Famotidine | Famotidine | 27 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 27 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 27 | suppressed |
| Acyclovir | Acyclovir | 26 | suppressed |
| Spironolactone | Spironolactone | 26 | suppressed |
| Finasteride | Finasteride | 25 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 24 | suppressed |
| Mirtazapine | Mirtazapine | 23 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 23 | 18 |
| Xtampza Er | Oxycodone Myristate | 23 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 22 | 13 |
| Irbesartan | Irbesartan | 21 | suppressed |
| Lactulose | Lactulose | 21 | suppressed |
| Mupirocin | Mupirocin | 21 | 13 |
| Ipratropium Bromide | Ipratropium Bromide | 20 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 20 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 20 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 19 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Bupropion Xl | Bupropion Hcl | 18 | suppressed |
| Glipizide | Glipizide | 18 | suppressed |
| Lamotrigine | Lamotrigine | 18 | suppressed |
| Meloxicam | Meloxicam | 18 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 18 | suppressed |
| Levofloxacin | Levofloxacin | 17 | 14 |
| Lidocaine | Lidocaine | 17 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Ramipril | Ramipril | 16 | suppressed |
| Bumetanide | Bumetanide | 15 | suppressed |
| Januvia | Sitagliptin Phosphate | 15 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 15 | suppressed |
| Pregabalin | Pregabalin | 15 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 14 | suppressed |
| Carisoprodol | Carisoprodol | 14 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 14 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 14 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 13 | suppressed |
| Methotrexate | Methotrexate Sodium | 13 | suppressed |
| Sotalol | Sotalol Hcl | 13 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Testosterone | Testosterone | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Ezetimibe | Ezetimibe | 11 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $701.09 · 31 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, APTIMA, AREXVY, BEXSERO, BREZTRI, Belbuca, Cologuard Collection Kit, GEMTESA, INSPIRE, JARDIANCE, JATENZO, MOUNJARO, PENMENVY, SHINGRIX, Tlando, VRAYLAR, WaveWriter Alpha Prime 16, Xhance, ZENPEP, ZEPBOUND | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error